(Q61774244)
Statements
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia (English)
Stefano Buttiglieri
Alessandra Risso
Corrado Tarella
Silvia L Locatelli
Alessandro M Gianni